Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Entheon Biomedical (1XU) AI Stock Analysis

DE:1XU

Entheon Biomedical

(Frankfurt:1XU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-Free Balance SheetThe absence of reported debt reduces interest obligations and near-term refinancing pressure, giving the company greater financial flexibility than a similarly loss-making biotechnology business with leverage. This supports continued research activity while limiting one important source of balance-sheet risk.
Negative Factors
No Recent RevenueRevenue falling to zero in the latest 2024–2025 period shows that the company has not yet established recurring commercial sales. Without an operating revenue base, funding for research and regulatory work remains dependent on capital resources rather than internally generated business activity.

Entheon Biomedical (1XU) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%DE:1XU-31.82%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 486.76K
Dividend Yield
―
Average Volume (3M)
175
Price to Earnings (P/E)
-4.3
Beta (1Y)
-0.81
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Entheon Biomedical Business Overview & Revenue Model

Company Description

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use di...

Entheon Biomedical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:1XU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:BETRTSE:BETR41NeutralCAD 154.50M-11.3634.90%――-266.67%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%DE:1XUTSE:BETRTSE:HAVNTSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:1XU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:1XUEntheon Biomedical Corp.0.03-0.02-37.50%
TSE:BETRBetterlife Pharma Inc.0.250.19316.67%
TSE:HAVNHavn Life Sciences Inc0.030.000.00%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.10-1.90-94.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.